Benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

David R. Gandara, MD, talks about the benefits of using Cyramza® (ramucirumab) plus docetaxel verus docetaxel alone in 2nd line NSCLC at Annual Meeting 2018.